Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meifang Zhang

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Journal of Medicinal Chemistry|August 16, 2022
Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus InfectionDongdong Chen, Xuefei Tan, Wenming Chen, et al.
Cancer Biology & Therapy|December 9, 2014
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapyQiaoling Sun, Jinghong Zhou, Zheng Zhang, et al.
Journal of Hepatology|January 1, 2023
Discovery of a first-in-class orally available HBV cccDNA inhibitorLi Wang, Qihui Zhu, Jitao David Zhang, et al.
Journal of Medicinal Chemistry|October 16, 2012
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor responseJason C Wong, Guozhi Tang, Xihan Wu, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Journal of Medicinal Chemistry|August 16, 2022
Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus InfectionDongdong Chen, Xuefei Tan, Wenming Chen, et al.
Cancer Biology & Therapy|December 9, 2014
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapyQiaoling Sun, Jinghong Zhou, Zheng Zhang, et al.
Journal of Hepatology|January 1, 2023
Discovery of a first-in-class orally available HBV cccDNA inhibitorLi Wang, Qihui Zhu, Jitao David Zhang, et al.
Journal of Medicinal Chemistry|October 16, 2012
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor responseJason C Wong, Guozhi Tang, Xihan Wu, et al.
Pageof 8